NO962503L - Use of penoxyphylline in the treatment of multiple sclerosis - Google Patents

Use of penoxyphylline in the treatment of multiple sclerosis

Info

Publication number
NO962503L
NO962503L NO962503A NO962503A NO962503L NO 962503 L NO962503 L NO 962503L NO 962503 A NO962503 A NO 962503A NO 962503 A NO962503 A NO 962503A NO 962503 L NO962503 L NO 962503L
Authority
NO
Norway
Prior art keywords
treatment
multiple sclerosis
penoxyphylline
pentoxyphylline
dosage
Prior art date
Application number
NO962503A
Other languages
Norwegian (no)
Other versions
NO962503D0 (en
Inventor
Peter Rieckmann
Original Assignee
Rentschler Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rentschler Arzneimittel filed Critical Rentschler Arzneimittel
Publication of NO962503D0 publication Critical patent/NO962503D0/en
Publication of NO962503L publication Critical patent/NO962503L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen vedrører anvendelse av pentoksyfyllin ved behandling av den rykkvis forlepende eller kronisk fremskridende form for multippel sklerose i kombinasjon med et kortikosteroid. Doseringen av pentoksyfyllin er 0,01 til 6,0 g/dag, og doseringen av kortikoidet er 0,01 til 1000 mg/dag.This invention relates to the use of pentoxyphylline in the treatment of the progressive or chronic progressive form of multiple sclerosis in combination with a corticosteroid. The dosage of pentoxyphylline is 0.01 to 6.0 g / day and the dosage of the corticoid is 0.01 to 1000 mg / day.

NO962503A 1993-12-16 1996-06-13 Use of penoxyphylline in the treatment of multiple sclerosis NO962503L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4343034A DE4343034C1 (en) 1993-12-16 1993-12-16 Use of pentoxifylline for the treatment of multiple sclerosis
PCT/EP1994/004188 WO1995016450A1 (en) 1993-12-16 1994-12-16 Use of pentoxifyllin in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
NO962503D0 NO962503D0 (en) 1996-06-13
NO962503L true NO962503L (en) 1996-06-13

Family

ID=6505251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962503A NO962503L (en) 1993-12-16 1996-06-13 Use of penoxyphylline in the treatment of multiple sclerosis

Country Status (10)

Country Link
EP (1) EP0734262A1 (en)
JP (1) JPH09506603A (en)
CA (1) CA2176848A1 (en)
CZ (1) CZ170896A3 (en)
DE (1) DE4343034C1 (en)
FI (1) FI962473A (en)
NO (1) NO962503L (en)
PL (1) PL314588A1 (en)
SK (1) SK76696A3 (en)
WO (1) WO1995016450A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19544768C1 (en) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Use of a combination of pentoxifylline with type I interferons to treat multiple sclerosis
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO2001087280A2 (en) * 2000-05-15 2001-11-22 Bayer Aktiengesellschaft Means for treating attacks of auto-immune diseases
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders
AU2013329421A1 (en) * 2012-10-09 2015-04-30 Biogen Ma Inc. Combination therapies and uses for treatment of demyelinating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases

Also Published As

Publication number Publication date
NO962503D0 (en) 1996-06-13
PL314588A1 (en) 1996-09-16
CZ170896A3 (en) 1997-01-15
SK76696A3 (en) 1997-04-09
FI962473A0 (en) 1996-06-14
JPH09506603A (en) 1997-06-30
WO1995016450A1 (en) 1995-06-22
DE4343034C1 (en) 1995-06-08
FI962473A (en) 1996-07-16
EP0734262A1 (en) 1996-10-02
CA2176848A1 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
ZA943744B (en) Therapeutic substituted guanidines
DK0566709T5 (en) Composition containing a tramadol material and acetaminophen and use thereof
MX9705235A (en) Substituted oxazolidine calpain and/or cathepsin b inhibitors.
ES2128552T3 (en) COMBINATION OF AN INHIBITOR OF THE BIOSYNTHESIS OF CHOLESTEROL AND AN INHIBITOR OF THE ABSORPTION OF BETA-LACTAMA CHOLESTEROL.
DE69328771D1 (en) METHOD FOR INHIBITING CARCINOGENESIS BY TREATMENT WITH DEHYDROEPIANDROSTERONE AND ITS ANALOGS
DK0713701T3 (en) 2-Bromelatonin for the treatment of sleep disorders
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
SE9603725D0 (en) New teatment
KR950702120A (en) USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
MXPA94009086A (en) Therapeutic substituted guanidines.
NO931886L (en) USE OF AICA RIBOCID COMPOUNDS FOR TREATMENT / PREVENTION OF TISSUE DAMAGES CAUSED BY REDUCED BLOOD FLOOD
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
KR960030947A (en) src Use of SH2-specific compounds for the treatment of bone resorption diseases
NO962503L (en) Use of penoxyphylline in the treatment of multiple sclerosis
MD960168A (en) Method for treatment of viral infections and compounds therefor
NO934832L (en) Pharmaceutical composition for the prevention or treatment of arterioscherosis
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
DK0862454T3 (en) CTLA-8 in combination with G-CSF or with G-CSF and IL-6 and use of CTLA-8 to treat infections
HUP9801628A2 (en) Therapeutic composition for arthritis
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
ATE315398T1 (en) SYNERGISTIC COMPOSITIONS CONTAINING GOLD AND A CORTICOSTEROID.